Protocol No 7 2020. November 26 th 2020
Password-BoardProtocol-7-2020
Regenics AS have developed clinical proof of efficacy and safety in human 2 degree burn wounds for our products Collex® and Vernex®.
The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.
